[1]
|
Palumbo, A. and Anderson, K. (2011) Multiple Myeloma. The New England Journal of Medicine, 364, 1046-1060.
https://doi.org/10.1056/NEJMra1011442
|
[2]
|
Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., et al. (2014) In-ternational Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. The Lancet Oncology, 15, e538-e548.
https://doi.org/10.1016/S1470-2045(14)70442-5
|
[3]
|
Varettoni, M., Corso, A., Pica, G., et al. (2010) Incidence, Presenting Features and Outcome of Extramedullary Disease in Multiple Myeloma: A Longitudinal Study on 1003 Con-secutive Patients. Annals of Oncology, 21, 325-330.
https://doi.org/10.1093/annonc/mdp329
|
[4]
|
Short, K.D., Rajkumar, S.V., Larson, D., et al. (2011) Incidence of Extramedullary Disease in Patients with Multiple Myeloma in the Era of Novel Therapy, and the Activity of Pomalido-mide on Extramedullary Myeloma. Leukemia, 25, 906-908. https://doi.org/10.1038/leu.2011.29
|
[5]
|
Giannakoulas, N., Ntanasis-Stathopoulos, I. and Terpos, E. (2021) The Role of Marrow Microenvironment in the Growth and Devel-opment of Malignant Plasma Cells in Multiple Myeloma. International Journal of Molecular Sciences, 22, 4462. https://doi.org/10.3390/ijms22094462
|
[6]
|
Francesco, D.M., Christina, Y., Annamaria, C., et al. (2021) Mapping the High-Risk Multiple Myeloma Cell Surface Proteome Identifies T-Cell Inhibitory Receptors for Immune Targeting. Blood, 138, 265.
https://doi.org/10.1182/blood-2021-147483
|
[7]
|
Alaterre, E., Raimbault, S., Goldschmidt, H., et al. (2017) CD24, CD27, CD36 and CD302 Gene Expression for Outcome Prediction in Patients with Multiple Myeloma. Oncotarget, 8, 98931-98944.
https://doi.org/10.18632/oncotarget.22131
|
[8]
|
Flores-Montero, J., Sanoja-Flores, L., Paiva, B., et al. (2017) Next Generation Flow for Highly Sensitive and Standardized Detection of Minimal Residual Disease in Multiple Myeloma. Leukemia, 31, 2094-2103.
https://doi.org/10.1038/leu.2017.29
|
[9]
|
Deaglio, S., Mehta, K. and Malavasi, F. (2001) Human CD38: A (r)evolutionary Story of Enzymes and Receptors. Leukemia Research, 25, 1-12. https://doi.org/10.1016/S0145-2126(00)00093-X
|
[10]
|
Costa, F., Dalla Palma, B. and Giuliani, N. (2019) CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeu-tic Agents. Cells, 8, 1632.
https://doi.org/10.3390/cells8121632
|
[11]
|
Saltarella, I., Desantis, V., Melaccio, A., et al. (2020) Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. Cells, 9, 167. https://doi.org/10.3390/cells9010167
|
[12]
|
Van de Donk, N.W., Janmaat, M.L., Mutis, T., et al. (2016) Monoclonal Antibodies Targeting CD38 in Hematological Malignancies and Beyond. Immunological Reviews, 270, 95-112. https://doi.org/10.1111/imr.12389
|
[13]
|
Nooka, A.K., Kaufman, J.L., Hofmeister, C.C., et al. (2019) Daratumumab in Multiple Myeloma. Cancer, 125, 2364-2382.
https://doi.org/10.1002/cncr.32065
|
[14]
|
Lebel, E., Nachmias, B., Pick, M., et al. (2022) Understanding the Bioac-tivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma. Journal of Clinical Medi-cine, 11, 1809.
https://doi.org/10.3390/jcm11071809
|
[15]
|
Akhmetzyanova, I., Mccarron, M.J., Parekh, S., et al. (2020) Dynamic CD138 Surface Expression Regulates Switch between Myeloma Growth and Dissemination. Leukemia, 34, 245-256. https://doi.org/10.1038/s41375-019-0519-4
|
[16]
|
Trowbridge, I.S. and Thomas, M.L. (1994) CD45: An Emerging Role as a Protein Tyrosine Phosphatase Required for Lymphocyte Activation and Development. Annual Review of Im-munology, 12, 85-116.
https://doi.org/10.1146/annurev.iy.12.040194.000505
|
[17]
|
Pellat-Deceunynck, C. and Bataille, R. (2004) Normal and Malignant Human Plasma Cells: Proliferation, Differentiation, and Expansions in Relation to CD45 Expression. Blood Cells, Molecules, and Diseases, 32, 293-301.
https://doi.org/10.1016/j.bcmd.2003.12.001
|
[18]
|
Kumar, S., Rajkumar, S.V., Kimlinger, T., et al. (2005) CD45 Expression by Bone Marrow Plasma Cells in Multiple Myeloma: Clinical and Biological Correlations. Leukemia, 19, 1466-1470. https://doi.org/10.1038/sj.leu.2403823
|
[19]
|
Gonsalves, W.I., Timm, M.M., Rajkumar, S.V., et al. (2016) The Prognostic Significance of CD45 Expression by Clonal Bone Marrow Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma. Leukemia Research, 44, 32-39. https://doi.org/10.1016/j.leukres.2016.03.003
|
[20]
|
Pick, M., Vainstein, V., Goldschmidt, N., et al. (2018) Daratu-mumab Resistance Is Frequent in Advanced-Stage Multiple Myeloma Patients Irrespective of CD38 Expression and Is Related to Dismal Prognosis. European Journal of Haematology, 100, 494-501. https://doi.org/10.1111/ejh.13046
|
[21]
|
Moreau, P., Robillard, N., Avet-Loiseau, H., et al. (2004) Patients with CD45 Negative Multiple Myeloma Receiving High-Dose Therapy Have a Shorter Survival than Those with CD45 Posi-tive Multiple Myeloma. Haematologica, 89, 547-551.
|
[22]
|
Agematsu, K., Nagumo, H., Oguchi, Y., et al. (1998) Gener-ation of Plasma Cells from Peripheral Blood Memory B Cells: Synergistic Effect of Interleukin-10 and CD27/CD70 In-teraction. Blood, 91, 173-180.
https://doi.org/10.1182/blood.V91.1.173
|
[23]
|
Guikema, J.E., Hovenga, S., Vellenga, E., et al. (2003) CD27 Is Heterogeneously Expressed in Multiple Myeloma: Low CD27 Expression in Patients with High-Risk Disease. British Journal of Haematology, 121, 36-43.
https://doi.org/10.1046/j.1365-2141.2003.04260.x
|
[24]
|
Chu, B., Bao, L., Wang, Y., et al. (2020) CD27 Antigen Negative Expression Indicates Poor Prognosis in Newly Diagnosed Multiple Myeloma. Clinical Immunology, 213, Arti-cle ID: 108363.
https://doi.org/10.1016/j.clim.2020.108363
|
[25]
|
Wang, K., Wei, G. and Liu, D. (2012) CD19: A Biomarker for B Cell Development, Lymphoma Diagnosis and Therapy. Experimental Hematology & Oncology, 1, 36. https://doi.org/10.1186/2162-3619-1-36
|
[26]
|
Barwick, B.G., Gupta, V.A., Vertino, P.M., et al. (2019) Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Frontiers in Immunology, 10, 1121. https://doi.org/10.3389/fimmu.2019.01121
|
[27]
|
Gao, M., Kong, Y., Yang, G., et al. (2016) Multiple Myeloma Cancer Stem Cells. Oncotarget, 7, 35466-35477.
https://doi.org/10.18632/oncotarget.8154
|
[28]
|
Johnsen, H.E., Bøgsted, M., Schmitz, A., et al. (2016) The Myeloma Stem Cell Concept, Revisited: From Phenomenology to Operational Terms. Haematologica, 101, 1451-1459. https://doi.org/10.3324/haematol.2015.138826
|
[29]
|
Garfall, A.L., Maus, M.V., Hwang, W.T., et al. (2015) Chi-meric Antigen Receptor T Cells against CD19 for Multiple Myeloma. The New England Journal of Medicine, 373, 1040-1047. https://doi.org/10.1056/NEJMoa1504542
|
[30]
|
Bahlis, N.J., King, A.M., Kolonias, D., et al. (2007) CD28-Mediated Regulation of Multiple Myeloma Cell Proliferation and Survival. Blood, 109, 5002-5010. https://doi.org/10.1182/blood-2006-03-012542
|
[31]
|
Zhang, P.P., Li, J.J., Hu, Z.L., et al. (2022) Clinical Signifi-cance of CD28 Expression in Newly Diagnosed Multiple Myeloma. Journal of Experimental Hematology, 30, 1785-1790.
|
[32]
|
Li, L., Li, X., Shang, A., et al. (2022) Prognostic Significance of CD56 Antigen in Newly Diagnosed Multiple Myeloma: A Real-World Retrospective Study. Medicine (Baltimore), 101, e30988.
https://doi.org/10.1097/MD.0000000000030988
|
[33]
|
Ngo, N.T., Brodie, C., Giles, C., et al. (2009) The Signifi-cance of Tumour Cell Immunophenotype in Myeloma and Its Impact on Clinical Outcome. Journal of Clinical Pathology, 62, 1009-1015. https://doi.org/10.1136/jcp.2009.065128
|
[34]
|
Koumpis, E., Tassi, I., Malea, T., et al. (2021) CD56 Expression in Multiple Myeloma: Correlation with Poor Prognostic Markers but No Effect on Outcome. Pathology Re-search and Practice, 225, Article ID: 153567.
https://doi.org/10.1016/j.prp.2021.153567
|
[35]
|
Dragoș, M.L., Ivanov, I.C., Mențel, M., et al. (2022) Prognostic Value of Association of Copy Number Alterations and Cell-Surface Expression Markers in Newly Diagnosed Multiple Myeloma Patients. International Journal of Molecular Sciences, 23, 7530. https://doi.org/10.3390/ijms23147530
|
[36]
|
Bataille, R., Pellat-Deceunynck, C., Robillard, N., et al. (2008) CD117 (c-kit) Is Aberrantly Expressed in a Subset of MGUS and Multiple Myeloma with Unexpectedly Good Prognosis. Leu-kemia Research, 32, 379-382.
https://doi.org/10.1016/j.leukres.2007.07.016
|
[37]
|
Zismanov, V., Drucker, L., Attar-Schneider, O., et al. (2012) Tetraspanins Stimulate Protein Synthesis in Myeloma Cell Lines. Journal of Cellular Biochemistry, 113, 2500-2510. https://doi.org/10.1002/jcb.24126
|
[38]
|
Paiva, B., Gutiérrez, N.C., Chen, X., et al. (2012) Clinical Significance of CD81 Expression by Clonal Plasma Cells in High-Risk Smoldering and Symptomatic Multiple Myeloma Patients. Leukemia, 26, 1862-1869.
https://doi.org/10.1038/leu.2012.42
|
[39]
|
Arana, P., Paiva, B., Cedena, M.T., et al. (2018) Prognostic Value of An-tigen Expression in Multiple Myeloma: A PETHEMA/GEM Study on 1265 Patients Enrolled in Four Consecutive Clin-ical Trials. Leukemia, 32, 971-978.
https://doi.org/10.1038/leu.2017.320
|
[40]
|
Kristiansen, G., Sammar, M. and Altevogt, P. (2004) Tumour Biological Aspects of CD24, a Mucin-Like Adhesion Molecule. Journal of Molecular Histology, 35, 255-262. https://doi.org/10.1023/B:HIJO.0000032357.16261.c5
|
[41]
|
Gross Even-Zohar, N., Pick, M., Hofstetter, L., et al. (2022) CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival. Journal of Clinical Medicine, 11, 2913. https://doi.org/10.3390/jcm11102913
|